• 1
    Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 1990; 50: 4417-4422.
  • 2
    Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-b-D-arabinofuranosylcytosine. Cancer Res. 1988; 48: 4024-4031.
  • 3
    Shewach DS, Reynolds KK, Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol. 1992; 42: 518-524.
  • 4
    Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol. 1990; 38: 567-572.
  • 5
    Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46:762-766.
  • 6
    Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991; 51: 6110-6117.
  • 7
    Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol. 1995; 36: 181-188.
  • 8
    Schy WE, Hertel LW, Kroin JS, Bloom LB, Goodman MF, Richardson FC. Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′—5′exonuclease-) fragment. Cancer Res. 1993; 53: 4582-4587.
  • 9
    Heinemann V, Xu YZ, Chubb S, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992; 52: 533-539.
  • 10
    Burris NHA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
  • 11
    Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000; 18: 122-130.
  • 12
    Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15: 3394-3398.
  • 13
    Rockwell S, Grindey GB. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res. 1992; 4: 151-155.
  • 14
    Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994; 54: 3218-3223.
  • 15
    Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine). Clin Cancer Res. 1997; 3: 777-782.
  • 16
    Abbruzzese JL, Grunewald R, Weeks EA, et al. A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991; 9: 491-498.
  • 17
    Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991; 27: 258-262.
  • 18
    Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996; 34: 867-872.
  • 19
    Rosier JF, Beauduin M, Bruniaux M, et al. The effect of 2′-2′ difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity. Int J Radiat Biol. 1999; 75: 245-251.
  • 20
    McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996; 88: 1193-1203.
  • 21
    Lawrence TS, Davis MA, Normolle DP. Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed-field gel electrophoresis. Radiat Res. 1995; 144: 282-287.
  • 22
    Gregoire V, Beauduin M, Bruniaux M, De Coster B, Octave Prignot M, Scalliet P. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis. Int J Radiat Biol. 1998; 73: 511-520.
  • 23
    Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res. 2000; 60: 6080-6088.
  • 24
    Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 1998; 41: 875-882.
  • 25
    Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine)-mediated radiosensitization. Clin Cancer Res. 2001; 7: 314-319.
  • 26
    Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 1999; 59: 107-114.
  • 27
    Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys. 1999; 44: 1125-1135.
  • 28
    Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 2000; 47: 785-791.
  • 29
    Rothenberg ML, Moore MJ, Cripps MC, et al. A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996; 7: 347-353.
  • 30
    Scalliet P, Goor C, Galdermans D, et al. Gemcitabine (Gemzar®) with thoracic radiotherapy: a Phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 499a.
  • 31
    Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999; 17: 2208-2212.
  • 32
    Poplin EA, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC)–gemcitabine: a Phase I study. Invest New Drugs. 1992; 10: 165-170.
  • 33
    Blackstock AW, Tempero MA, Niedwiecki D, Hollis DR, Mayer RJ, Tepper JE. Cancer and Leukemia Group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas[abstract]. Proc Am Soc Clin Oncol. 2001; 20: 158a.
  • 34
    McGinn CJ, Smith DC, Szarka CE, et al. A Phase I study of gemcitabine (GEM) in combination with radiation therapy (RT) in patients with localized, unresectable pancreatic cancer[abstract]. Proc Am Soc Clin Oncol. 1998; 17: 264a.
  • 35
    Hoffman JP, McGinn CJ, Szarka C, et al. A Phase I study of preoperative gemcitabine (GEM) with radiation therapy (RT) followed by postoperative GEM in patients with localized, resectable pancreatic adenocarcinoma[abstract]. Proc Am Soc Clin Oncol. 1998; 17: 283a.
  • 36
    Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001; 7: 2246-2253.
  • 37
    Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000; 18: 3384-3389.
  • 38
    McGinn CJ, Zalupski MM, Shureiqi I, et al. A Phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001; 19: 4202-4208.
  • 39
    Gunderson LL, Martin JK, Kvols LK, et al. Intraoperative and external beam irradiation +/− 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1987; 13: 319-329.
  • 40
    Robertson JM, Marsh L, TenHaken RK, Lawrence TS. The clinical application of a non-axial treatment plan for pancreatic and biliary malignancies. Radiother Oncol. 1992; 24: 198-200.
  • 41
    Higgins D, Sohn JW, Fine RM, Schell MC. Three-dimensional conformal pancreas treatment: comparison of four- to six-field techniques. Int J Radiat Oncol Biol Phys. 1995; 31: 605-609.
  • 42
    Lichter AS, Lawrence TS. Recent advances in radiation oncology. N Engl J Med. 1995; 32: 371-379.
  • 43
    McGinn CJ, Zalupski MM. Combined-modality therapy in pancreatic cancer: current status and future directions. Cancer J. 2001; 7: 338-348.